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Abstract
Introduction: The detection of circulating tumour cells (CTCs) in the peripheral blood and disseminated tumour
cells (DTCs) in the bone marrow are promising prognostic tools for risk stratification in early breast cancer. There is,
however, a need for further validation of these techniques in larger patient cohorts with adequate follow-up
periods.
Methods: We assayed CTCs and DTCs at primary surgery in 733 stage I or II breast cancer patients with a median
follow-up time of 7.6 years. CTCs were detected in samples of peripheral blood mononuclear cells previously
stored in liquid-nitrogen using a previously-developed multi-marker quantitative PCR (QPCR)-based assay. DTCs
were detected in bone marrow samples by immunocytochemical analysis using anti-cytokeratin antibodies.
Results: CTCs were detected in 7.9% of patients, while DTCs were found in 11.7%. Both CTC and DTC positivity
predicted poor metastasis-free survival (MFS) and breast cancer-specific survival (BCSS); MFS hazard ratio (HR) = 2.4
(P < 0.001)/1.9 (P = 0.006), and BCSS HR = 2.5 (P < 0.001)/2.3 (P = 0.01), for CTC/DTC status, respectively).
Multivariate analyses demonstrated that CTC status was an independent prognostic variable for both MFS and
BCSS. CTC status also identified a subset of patients with significantly poorer outcome among low-risk node
negative patients that did not receive adjuvant systemic therapy (MFS HR 2.3 (P = 0.039), BCSS HR 2.9 (P = 0.017)).
Using both tests provided increased prognostic information and indicated different relevance within biologically
dissimilar breast cancer subtypes.
Conclusions: These results support the use of CTC analysis in early breast cancer to generate clinically useful
prognostic information.
Introduction
In recent years breast cancer survival rates have been
steadily increasing, partly due to earlier diagnoses as a
result of increased awareness and widespread mammo-
graphy screening programmes. Despite these advances,
approximately one-third of patients will develop distant
metastasis, which represents the terminal step in the
progression of the disease. The relative paucity of
accurate prognostic tests has made it difficult to identify
these high-risk patients to allow for more optimized
adjuvant treatment decisions. Similarly, many patients at
low risk of developing disseminated disease undergo
toxic adjuvant chemotherapy treatments that are of little
benefit. There is consequently a need for new prognostic
tests with significantly increased sensitivity and specifi-
city, particularly for those patients at the early stages of
their disease.
Tumour cells in the bone marrow (disseminated
tumour cells (DTCs)) or circulating in the peripheral
blood (circulating tumour cells (CTCs)), are potential
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represent important targets of such tests [1-12]. Indeed,
the detection of CTCs and DTCs has been associated
with both disease progression in metastatic breast can-
cer [13-15], as well as disease recurrence and distant
spread in early-stage breast cancer [1,3,5,6,16]. Bone
marrow has traditionally been the primary compartment
in which the prognostic value of the detection of these
cells has been investigated, as it is a common homing
organ for tumour cells of epithelial origin [17]. While
the detection of DTC is of prognostic significance
[1,3,5], it has the inherent disadvantage of needing an
invasive procedure for sample collection and, addition-
ally, is less suitable for serial sampling for monitoring
adjuvant treatment response. The use of peripheral
blood as an alternative sampling material has, therefore,
gained significant interest in recent years as it does not
suffer from these drawbacks. However, there remains a
need for good quality studies to confirm the clinical
relevance of CTCs in larger patient cohorts, particularly
in comparison to DTCs. So far relatively few such stu-
dies in early breast cancer have included mature out-
come data. Furthermore, only limited data exist on the
comparison of CTCs and DTCs in this context, and stu-
dies have shown variable results [7,18,19]. Whether
CTC detection could replace DTC detection is still an
open question, and the value of CTCs versus DTCs may
differ among patients as a consequence of different
tumour biology and/or dissemination characteristics.
In the current study, we used our previously-devel-
oped [2,20] multi-marker QPCR-based CTC assay on
thawed samples of liquid nitrogen-stored peripheral
blood mononuclear cells (PBMC) from 733 early-stage
breast cancer patients collected at the time of diagnosis.
In addition, this patient series previously had bone mar-
row samples assayed for DTCs [1], which afforded an
o p p o r t u n i t yt od i r e c t l yc o m p a r et h ep r o g n o s t i cr e l e -
vance of CTC and DTC detection in the same large
patient group.
Materials and methods
Patient and sample selection
Between May 1995 and December 1998, samples of per-
ipheral blood and bone marrow were collected from 920
stage I-II primary breast cancer patients immediately
prior to primary surgery, at five hospitals in Norway
(Ullevål University Hospital (now Oslo University Hos-
pital Ullevål), Norwegian Radium Hospital (now Oslo
University Hospital Norwegian Radium Hospital),
Bærum Hospital, Aker University Hospital, and Bus-
kerud Hospital), as described previously [1]. After
excluding patients from whom peripheral blood mono-
nuclear cells (PBMC) were either unavailable for this
study (n = 149) or who were eligible for and/or received
preoperative systemic therapy (pT3/4 patients; n =3 8 ) ,
which would likely distort the true CTC levels, PBMC
were thawed from liquid nitrogen storage for CTC ana-
lysis. Bone marrow samples from the same patients (n =
733) had previously been analysed for the presence of
DTCs [1]. Patients were treated with breast-conserving
surgery or breast ablation and axillary clearance in addi-
tion to adjuvant therapy where required, as described in
Table 1. Systemic adjuvant treatment was given accord-
ing to the national guidelines between 1995 and 1998.
Patients with node negative disease having either
tumours ≤ 2c mo rg r a d e1t u m o u r s2t o5c mi nd i a -
meter did not receive systemic adjuvant treatment. In
addition, patients > 65 years of age did not receive che-
motherapy. The standard adjuvant chemotherapy regi-
men consisted of six cycles (3 qw) of intravenous
cyclophosphamide 600 mg/m
2, methotrexate 40 mg/m
2,
and fluorouracil 600 mg/m
2. Ten patients received high-
dose chemotherapy. Tamoxifen was used as endocrine
therapy in hormone receptor-positive patients. Radio-
therapy was offered after breast-conserving surgery for
all patients and after mastectomy for node-positive pre-
menopausal patients and postmenopausal patients with
four or more positive lymph nodes. The follow-up con-
sisted of clinical examination at 6- to 12-month intervals
at the hospital outpatient departments or by the
patients’ primary doctors, with mammography annually.
Further diagnostic work-up was performed only if the
patients had symptoms or signs of progression. The
median follow-up time for metastasis-free survival was
7.1 years, and for breast cancer-specific survival 8.3
years. Written informed consent was obtained from all
participants and the study was approved by the Regional
Ethic Committee.
Control subjects
For the CTC study, 16 patients with metastatic breast
cancer (M1 disease, according to the Union Internatio-
nale Contre le Cancer criteria) were included as clinical
“positive controls” as based on our previous studies [2]
the majority (> 90%) were expected to have circulating
tumour cells. They were invited to participate if they
were between treatments or soon to start subsequent
palliative treatment modality. A total of 28 samples of
peripheral blood from healthy controls into which dif-
ferent numbers (5 to 1,000) of cultured breast tumour
cells derived from a mixture of six breast cancer cell
lines (MCF7, CAMA1, T47D, SKBR3, ZR-75-1, and
MDA-MB-231) were also tested in parallel as a second
positive control group. Twenty-five healthy (negative)
control subjects matched for gender and age and ran-
domly selected from hospital and scientific staff were
also freshly collected. Mononuclear cells from these
control groups were separated and stored frozen for up
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Page 2 of 11Table 1 Clinical characteristics of the stage I to II breast cancer patients included in the study
All patients CTC positive CTC negative
Number Percent Number Percent Number Percent P-value*
Number: 733 100% 58 7.9% 675 92.1%
Age: < 35 15 2.0% 1 1.7% 14 2.1% 0.503
35 to 45 89 12.1% 10 17.2% 79 11.7%
45 to 55 203 27.7% 18 31.0% 185 27.4%
> 55 426 58.1% 29 50.0% 397 58.8%
Tumour size: pT1 (< 2.0 cm) 405 55.3% 30 51.7% 375 55.6% 0.373
§
pT2 (2.0 to 5.0 cm) 225 30.7% 20 34.5% 205 30.4%
pT3 (> 5.0 cm) 2 0.3% 2 3.4% 0 0%
pTX 60 8.2% 3 5.2% 57 8.4%
Histological grade: Grade 1 187 25.5% 9 15.5% 178 26.4% 0.186
Grade 2 350 47.7% 29 50.0% 321 47.6%
Grade 3 186 25.4% 18 31.0% 168 24.9%
Unknown 10 1.4% 2 3.4% 8 1.2%
ER status: Positive 516 70.4% 31 53.4% 485 71.9% 0.002
Negative 179 24.4% 24 41.4% 155 23.0%
Unknown 38 5.2% 3 5.2% 35 5.2%
PR status: Positive 401 54.7% 25 43.1% 376 55.7% 0.046
Negative 288 39.3% 30 51.7% 258 38.2%
Unknown 44 6.0% 3 5.2% 41 6.1%
HER2 status: Positive 83 11.3% 15 25.9% 68 10.1% < 0.001
Negative 610 83.2% 40 69.0% 570 84.4%
Unknown 40 5.5% 3 5.2% 37 5.5%
Node status: pN0 483 65.9% 34 58.6% 449 66.5% 0.089
pN1 150 20.5% 11 19.0% 139 20.6%
pN2 53 7.2% 9 15.5% 44 6.5%
pN3 22 3.0% 3 5.2% 19 2.8%
pNX 25 3.4% 1 1.7% 24 3.6%
Vascular invasion: Yes 116 15.8% 12 20.7% 104 15.4% 0.171
No 524 71.5% 35 60.3% 489 72.4%
Unknown 93 12.7% 11 19.0% 82 12.1%
Bone marrow status: Positive 86 11.7% 17 29.3% 69 10.2% < 0.001
Negative 605 82.5% 35 60.3% 570 84.4%
Unknown 42 5.7% 6 10.3% 36 5.3%
Adjuvant systemic treatment: No treatment 391 53.3% 28 48.3% 363 53.8% 0.392
Chemo +/- Hormonal 155 21.1% 16 27.6% 139 20.6%
Hormonal therapy Only 164 22.4% 11 19.0% 153 22.7%
Unknown 23 3.1% 3 5.2% 20 3.0%
Metastasis: Number 149 20.3% 22 37.9% 127 18.8% 0.001
Median time to event 36.4 months 30.8 months 37.2 months
Median followup time 84.3 months 78.6 months 85.2 months
Breast cancer-specific deaths: Number 122 16.6% 19 32.8% 103 15.3% < 0.001
Median time to event 42.9 months 54.3 months 42.0 months
Median followup time 99.2 months 94.1 months 99.2 months
*P-value (Pearson Chi-squared test).
§ = Chi-squared analysis included pT1 and pT2 tumours only.
CTC, circulating tumour cell; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor
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tions of the patient samples, before being thawed and
assayed. For the DTC study, bone marrows from 98
healthy controls were assayed.
Sampling and processing of peripheral blood (PB)
A total of 50 mL of blood was collected immediately
prior to primary surgery. Mononuclear cells, including
any tumour cells present, were separated from the
whole blood samples using Ficoll Hypaque (BD,
Breda, Netherlands) and stored frozen in aliquots of
20 × 10
6 cells (except from 30 patients, from which
less than 20 × 10
6 cells were available) in liquid nitro-
gen until tumour cell enrichment (10 to 15 years
later). Tumour cells were separated from a single ali-
quot of peripheral blood mononuclear cells (PBMCs)
using anti-EpCAM (clone HEA-125) and anti-ErbB2
Micro Beads (MACS
®; Miltenyi Biotec, Leiden, Neth-
erlands) according to the manufacturer’s instructions.
In brief, beads were incubated with the PBMCs for 30
minutes at 4°C, after which labelled cells were col-
lected on a magnetic separation column. After
removal of the column from the magnetic field, the
retained EpCAM
+ and/or ErbB2
+ cells were eluted,
and stored at -70°C in lysis buffer (5 M Guanidine
thiocyanate (Merck, Darmstadt, Germany), pH 6.8,
0.05 M tris, 0.02 M EDTA, 1.3% Triton) until mRNA
isolation and cDNA synthesis.
mRNA isolation and cDNA synthesis
Total RNA was precipitated from the cell lysate and dis-
solved in lysis buffer from the μMACS™ One-step
cDNA kit (Miltenyi Biotec). Oligo(dT) Micro Beads
were added and the mixture placed onto the μMACS
column in the thermo MACS™ Separator (Miltenyi Bio-
tec, Leiden, Netherlands). The isolated mRNA was
directly converted into cDNA as per the manufacturer’s
instructions, with an additional elution with 20 μlo f
elution buffer, resulting in a total volume of 70 μl.
Quantitative real-time PCR
Quantitative real-time PCR primers (Sigma Genosys,
Cambridge, UK) and 5’-fluorescently FAM-labelled
probes (Applied Biosystems, Nieuwerkerk a/d IJssel, The
Netherlands) were designed using the Perkin Elmer Pri-
mer Express
® software (PE, Foster City, CA, USA) based
on the published sequences of CK19, p1B, EGP-2, PS2,
mammaglobin and SBEM as previously described [20]
(Table 2). All primers were designed to be intron-span-
ning to preclude amplification of genomic DNA. Com-
mercially available primers and probes for the
“housekeeping” genes b-actin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Applied Biosys-
tems) were also used.
Serially diluted cDNA synthesized from the amplified
RNA of a pool of 82 snap frozen breast cancer tissues
was used to generate standard curves for control and
marker gene expression. For all cDNA dilutions, fluores-
cence was detected from 0 to 50 PCR cycles for the
control and marker genes in single-plex reactions, which
allowed the deduction of the CT-value (threshold cycle)
for each product. The CT-value is the PCR cycle at
which a significant increase in fluorescence is detected
due to the exponential accumulation of PCR products
and is represented in arbitrary units (TaqMan Universal
PCR Master Mix Protocol, Applied Biosystems) [21].
The “housekeeping” genes b-actin and GAPDH were
used to confirm reaction efficiency. Each measurement
was performed in triplicate. Quality control measures
for the PCR reactions included the addition of a geno-
mic DNA control and a non-template control.
Quadratic discriminant analysis (QDA) ‘CTC score’
calculation
QDA was used to calculate a ‘CTC score’ representing
CTC presence or absence for each sample, as previously
described [22,23], using the expression data of the four
b e s tm a r k e rg e n e s( C K 1 9 ,p 1 B ,E G Pa n dM m G l ) .Q D A
is a statistical approach to find the combination of
Table 2 Primer sequences for the six marker genes used for CTC detection
Gene Accession Sequence Probe (5’FAM-3’TAMRA)
p1B [Genbank:
L15203]
Sense: CTGAGGAGTACGTGGGCCTG Antisense:
AGTCCACCCTGTCCTTGGC
CTGCAAACCAGTGTGCCGTGCC
PS2 [Genbank:
X00474]
Sense: GAGGCCCAGACAGAGACGTG Antisense:
CCCTGCAGAAGTGTCTAAAATTCA
CTGCTGTTTCGACGACACCGTTCG
CK19 [Genbank:
NM002276]
Sense: CTACAGCCACTACTACACGAC Antisense:
CAGAGCCTGTTCCGTCTCAAA
CACCATTGAGAACTCCAGGATTGTCCTGC
EGP2 [Genbank:
M32306]
Sense: CAGTTGGTGCACAAAATACTGTCA Antisense:
CCATTCATTTCTGCCTTCATCA
TTGCTCAAAGCTGGCTGCCAAATGTT
SBEM [Genbank:
AF414087]
Sense: CTCTTGGGGAGTTTTCCATCTTTCTG Antisense:
CTTCATCATCAGCAGGACCAGTAG
CCCAGAATCCGACAACAGCTGCTCC
MmGl [Genbank:
AF015224]
Sense: TTCTTAACCAAACGGATGAAACTCT Antisense:
GGTCTTGCAGAAAGTTAAAATAAATCAC
TGCTGTCATATATTAATTGCATAAACACCTCAACATTG
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marker genes), which leads to the optimal separation
between groups (in this case metastatic breast cancer
patients and healthy volunteers). It is a generalization of
Fisher’s Linear Discrimination Analysis (LDA), which
allows only linear functions [24]. A positive discriminant
score indicates the presence of tumour cells in a sample,
and conversely a negative discriminant score indicates
their absence. QPCR measurement and QDA data ana-
lysis in this way offer a simple and objective estimate of
tumour cell presence in a given sample.
Sampling and processing of bone marrow (BM)
The processing and analysis of DTC has been previously
described [1]. Briefly, BM was collected from patients
under general anaesthesia just before primary surgery
for suspected breast cancer. A total of 40 mL of BM
was aspirated from anterior and posterior iliac crests
bilaterally (10 mL per site) and after separation by den-
sity centrifugation, mononuclear cells (MNC) were col-
lected and cytospins were prepared (5 × 10
5 MNC/
slide). Four slides were incubated with the anticytokera-
tin monoclonal antibodies (mAbs) AE1 and AE3 (San-
bio, Uden, The Netherlands), and the same number of
slides were incubated with an isotype-specific irrelevant
control mAb. The visualization step included the alka-
line phosphatase/anti-alkaline phosphatase reaction, and
the slides were counterstained with hematoxylin to
visualize nuclear morphology. The cytospins were
manually screened by light microscopy by a single
pathologist (EB). The determination of the presence of
DTC was based on Consensus morphology criteria [25].
In the DTC-positive patients, a median of 1 cell was
detected, with a mean of 98 cells (range 1 to 7,500). Of
the bone marrow samples from 98 healthy controls, 4
contained ≥ 1 cell (3 with 1 cell, 1 with 2 cells) which
were scored positive by the described technique. Those
patients with a DTC positive event in the negative con-
trol (isotype specific), were excluded from DTC inter-
pretation in the specific test (AE1AE3), which improved
the specificity of the DTC analysis.
Statistical analysis
The primary endpoints for the survival analysis was
breast cancer-specific survival (BCSS), which was mea-
sured from the date of surgery to breast cancer-related
death or otherwise censored at the time of the last fol-
low-up visit or at non cancer-related death, and metas-
tasis-free survival (MFS), measured in the same way.
Kaplan-Meier survival curves for time to distant recur-
rences and breast cancer-specific death were plotted. P-
values were computed by the log-rank test. Cox propor-
tional hazards regression was used for univariate and
multivariate (stepwise backward elimination) analysis of
prognostic impact of relevant variables. For statistical
analysis, the SPSS (Version 15.0.1; SPSS, Inc, Chicago,
IL, USA) software was used.
Results
Detection of CTC
Results from a total of 733 stage I to II breast cancer
patients with biomaterial available at the time of surgery
for both CTC and DTC analysis are presented. For CTC
detection, samples of peripheral blood from a group of
healthy individuals (negative controls) and metastatic
breast cancer patients (positive controls) were processed
the same way as the patient samples. These were used
to calculate weights for each of the tumour marker
genes used in the CTC assay and to set the threshold of
CTC positivity. In an analogous fashion, 28 blood sam-
ples from healthy volunteers into which cultured breast
tumour cells were spiked were also investigated as posi-
tive controls, since all should contain detectable levels
of tumour marker gene expression. This sample set gen-
erated comparable tumour marker weights to the meta-
static patients. This analysis also demonstrated that the
a s s a yg a v eap o s i t i v eC T Cs c o r ew h e na sf e wa so n e
tumour cell per mL was present in the sample (data not
shown).
Using the above data to tune the QDA CTC score cal-
culation, 58 of the 733 (7.9%) patients had a positive
CTC score and determined CTC-positive, versus 0 out
of 25 healthy controls in the negative control group.
The CTC result was compared to clinical and histo-
pathological parameters, as well as the DTC status, as
described in Table 1. Patients determined to be CTC-
positive were significantly more likely to have ER-nega-
tive (P = 0.002 (Pearson Chi-square test)), PR-negative
(P = 0.046), HER2-positive (P < 0.001) tumours, and
have tumour cells present in the bone marrow (P <
0.001).
Circulating tumour cell status and patient outcome
The median observation period for the patients follow-
ing blood collection was 7.1 years for metastasis-free
survival, and 8.3 years for breast cancer-specific survival.
During these periods, 149 patients (20.3%) experienced
metastasis - 22 (37.9%) of the CTC-positive patients,
versus 127 (18.8%) of the CTC-negative patients (P =
0.001 (Pearson Chi-square test); Table 1). Cox regres-
sion analysis demonstrated that CTC status was a signif-
icant predictor of metastasis-free survival (MFS; hazard
ratio (HR) = 2.4, P < 0.001; 95% confidence interval (CI)
= 1.5 to 3.9; Figure 1A; Table 3). Similarly, 122 patients
(16.6%) died from their disease during the follow-up
period: 19 (32.8%) CTC-positive patients, versus 103
(15.3%) CTC-negative patients. CTC status was, there-
fore, also a significant prognostic factor for breast-
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CI = 1.5 to 4.3); Figure 1B; Table 3).
CTC status was next tested in a multivariate Cox
regression model, including DTC status and standard
prognostic clinical variables (lymph node status, histolo-
gical grade, tumour size, hormone receptor status, HER2
status, and vascular invasion). In the final model, CTC
status remained a significant prognostic factor for both
relapse-free survival and breast cancer-specific survival
(Table 4).
Within this cohort, 367 lymph node-negative patients
were considered at low risk of metastasis according to
the prevailing guidelines at the time of study accrual
and did not receive systemic adjuvant treatment. Of
Figure 1 Metastasis-free survival (A, C, E) and breast-cancer specific survival (B, D, F) for all,(A, B), lymph-node negative, (C, D), and
lymph-node positive (E, F) patients.
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nificantly higher risk of metastasis and breast cancer
death than those that were CTC-negative (MFS HR =
3.0, P = 0.014; BCSS HR = 3.6, P = 0.011) (Figure 2). In
the subgroup of patients receiving chemotherapy (with
or without hormonal treatment; n = 155), CTC status
was also prognostic (MFS HR = 2.3, P = 0.042; BCSS
HR = 3.1, P = 0.012). For patients treated with hormo-
nal therapy only (n = 164), survival differences accord-
ing to CTC status were not statistically significant (MFS
HR = 1.3, P = 0.701; BCSS HR = 1.7, P = 0.376).
Circulating tumour cell status versus disseminated
tumour cell status
Previously, we reported the clinical significance of DTC
status in this patient cohort (over a shorter follow-up
period) by immunocytochemical detection of cytokera-
tin-positive cells [1]. This allowed the direct comparison
of the prognostic value of CTC detection to DTC detec-
tion. Of the 733 patients included in the study, the bone
marrow samples of 86 patients (11.7%) contained DTCs.
In univariate analyses DTC status was also a significant
predictor of outcome, with a HR of 1.9 for MFS (P =
0.006) and 2.3 (P = 0.001) for BCSS (Table 3). However,
in the multivariate analyses including CTCs, DTC status
fell below the level of significance (Table 4). Patients in
whom tumour cells were detected in both peripheral
blood and bone marrow had a significantly poorer out-
come than those with tumour cells detected in only one
or neither compartment (MFS = 3.5, P =0 . 0 0 1 ;B C S S=
3.0, P = 0.008; Figure 3). In addition, those patients who
were exclusively CTC-positive or exclusively DTC-posi-
tive also had reduced survival as compared to patients
who were negative for both (CTC+/DTC- BCSS HR =
2.2, P = 0.015; MFS = 1.9, P = 0.034. CTC-/DTC+ BCSS
HR = 2.1, P = 0.003; MFS = 1.5, P = 0.127).
A subgroup univariate analysis revealed that DTC sta-
tus was only prognostic in lymph node-positive patients
(MFS HR = 2.1, P = 0.004 and BCSS HR = 2.1, P =
0.007), and not in lymph node-negative patients (MFS
HR = 0.6, P = 0.378 and BCSS HR = 1.0, P = 0.978).
CTC status however, appeared to be prognostic in both
groups (MFS HR = 2.1, P = 0.015; BCSS HR = 1.9, P =
0.045 for lymph-node positive patients, and MFS HR =
2.3, P =0 . 0 3 9 ;B C S SH R=2 . 9 ,P = 0.017 for lymph-
node negative patients; Figure 1). When patients were
subgrouped by ER, PR, and HER2 status, CTC status,
but not DTC status, was significantly associated with
survival for ER-negative and/or HER2-negative patients.
For ER-positive patients, those with the presence of
DTCs experienced reduced BCSS. This was not
observed for CTC positive patients. Both CTC and DTC
status were associated with MFS (Table 5). Of the 143
ER/PR/HER-negative ("triple negative”)p a t i e n t s ,C T C
status, but not DTC status, was prognostic for both
Table 3 Univariate Cox regression analysis of CTC and
DTC status for metastasis-free and breast cancer-specific
survival
Metastasis-free
survival
Breast cancer-specific
survival
Clinical variable HR P-value 95% CI HR P-value 95% CI
CTC status 2.4 < 0.001 1.5 to 3.9 2.5 < 0.001 1.5 to 4.3
DTC status 1.9 0.006 1.2 to 2.9 2.3 0.001 1.4 to 3.7
CI, confidence interval; CTC, circulating tumour cell; DTC, disseminated tumour
cell; HR, hazard ratio
Table 4 Multivariate Cox regression analysis of CTC and DTC status for metastasis-free and breast cancer-specific
survival
Relapse-free survival Breast cancer-specific survival
Clinical variable HR P-value 95% CI HR P-value 95% CI
CTC status (†) 1.8 0.043 1.0 to 3.3 1.9 0.032 1.1 to 3.6
DTC status (†)* * * * * *
Lymph nodes (vs pN0) < 0.001 < 0.001
- pN1 2.2 0.001 1.4 to 3.5 2.6 0.001 1.5 to 4.5
- pN2/3 3.2 < 0.001 1.8 to 5.5 3.8 < 0.001 2.1 to 7.0
Histological grade (vs I) 0.053 0.049
- grade II 2.0 0.094 0.9 to 4.5 1.6 0.324 0.6 to 4.3
- grade III 2.8 0.019 1.2 to 6.8 2.8 0.044 1.0 to 7.7
Tumour size (< 20 mm vs > 20 mm) 1.9 0.002 1.3 to 2.9 2.4 < 0.001 1.5 to 3.8
ER/PR status (‡) 1.7 0.028 1.1 to 2.7 1.9 0.018 1.1 to 3.1
HER2 status (†) * * * 1.8 0.024 1.1 to 3.1
Vascular Invasion (†) 1.6 0.048 1.0 to 2.5 1.8 0.015 1.1 to 3.0
*, not significant in final multivariate model; †, positive versus negative; ‡, both negative versus either or both positive
CI, confidence interval; CTC, circulating tumour cell; DTC, disseminated tumour cell; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR,
hazard ratio; PR, progesterone receptor
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respectively) and BCSS (HR = 2.4, P = 0.019 vs HR =
1.1, P = 0.846).
Discussion
We aimed to validate a previously-developed [2,20],
highly sensitive multi-marker QPCR-based CTC assay in
a large early-stage breast cancer patient cohort with
mature outcome data. Bone marrow samples from these
patients had previously been assayed for DTCs by
immunocytochemical analysis using anti-cytokeratin
antibodies [1]. This made it possible to also directly
compare the prognostic value of the detection of
tumour cells in the peripheral blood versus the bone
marrow in the same large patient group.
In this cohort of 733 early-stage breast cancer patients,
CTC status was a significant predictor of both metasta-
sis-free and breast cancer-specific survival, in agreement
with other studies [2,6,7,26,27]. To our knowledge, this is
the largest published study on CTCs with mature out-
come data. There was no significant difference in the dis-
tribution of many common clinical variables between
CTC-positive and CTC-negative patients, barring that
CTC-positive patients had tumours which were ER-nega-
tive, PR-negative and HER2-positive significantly more
often, in agreement with other studies [28]. CTC-positive
patients were in addition more likely to have tumour
cells present in both their bone marrow, in accordance
with the findings of Daskalaki et al.,P i e r g aet al.,a n d
Müller et al. [7,29,30] (Table 1).
Figure 2 Kaplan-Meier plot of metastasis-free survival (A) and breast cancer specific survival (B) in patients who did not receive
systemic adjuvant treatment (n = 367). The CTC-positive patients had a poorer MFS and BCSS than CTC-negative patients (MFS HR = 3.0, 95%
CI = 1.2 to 7.1, P = 0.014; BCSS HR = 3.6, 95% CI = 1.3 to 9.6, P = 0.011).
Figure 3 Kaplan-Meier plots demonstrating the effect of combining circulating and disseminated tumour cell status on metastasis-
free survival (A) and breast-cancer specific survival (B). Those patients in whom tumour cells were detected in both the peripheral blood
and bone marrow compartments have a significantly poorer survival compared to other groups (MFS = 3.5, P = 0.001; BCSS = 3.0, P = 0.008).
Molloy et al. Breast Cancer Research 2011, 13:R61
http://breast-cancer-research.com/content/13/3/R61
Page 8 of 11Importantly, multivariate analysis demonstrated that
CTC status provided prognostic information indepen-
dent of other common clinical variables (Table 4).
Furthermore, the CTC analysis discriminated outcome
among those patients deemed at sufficiently low-risk of
distant metastasis by traditional risk assessment to not
receive systemic treatment. Indeed, these “low-risk”
lymph node-negative CTC-positive patients had a five-
year BCSS of 75.0%, versus 93.0% for the CTC-negative
patients (Figure 2). The identification of such a poor
prognosis subgroup within a group of traditionally-
defined “low risk” patients indicates the potential value
of CTC detection in routine clinical use in conjunction
with other prognostic tests.
Our results show that immunomagnetic tumour cell
enrichment followed by multi-marker QPCR analyses on
samples of PBMCs stored frozen for up to 15 years pro-
vides valuable clinical data. As expected, some cellular
and nucleic acid degradation was observed in these sam-
ples after their removal from long-term storage, with
tumour marker gene expression lower, variance higher
(24-fold) and lower frequency of CTC positive cases
(7.9%) than that observed with our recent study using
fresh material from a similar patient group (n =8 2 )[ 2 ] .
None of the 25 healthy controls assayed were deter-
mined to be CTC-positive, which suggested high specifi-
city. On the other hand, it should be noted that the
possibility of occasional tumour marker gene expression
in non-malignant cells of breast cancer patients cannot
entirely be excluded, which may decrease true specificity
in a clinical setting.
Interestingly, while CTC status was correlated with
DTC status in these patients, it also provided additional
prognostic information and outperformed DTC status in
the multivariable analysis (Figure 3, Tables 4 and 5).
Keeping in mind the retrospective design of this study,
the presented results indicate that the CTC status espe-
cially improves the ability to predict outcome in the ER
negative subset. It is possible that CTCs and DTCs to
some extent reflect distinct aspects of the disease and
that their presence and relevance depend on the biology
of the underlying breast cancer: bone marrow is a com-
partment in which tumour cells may remain dormant
for many years [17], whereas peripheral blood represents
a transitory route for tumours that may be more rapidly
proliferating and/or actively migrating. This is consistent
with the observation that CTC-positive patients are sig-
nificantly more likely to have ER-/PR-/HER2+ (Table 1)
or triple negative tumours (P =0 . 0 0 3b yP e a r s o nC h i -
square), which tend to be more aggressive and exhibit
high proliferative capacity [31]. DTCs by comparison,
might have higher propensity to remain dormant but
viable for extended periods, and, therefore, be more pre-
dictive of metastasis or relapse at later time points. This
is consistent with our previous study in which the DTC
status of a subset of patients from the current cohort
was correlated to molecular subtype [32]. It was found
that prognostic DTC status was most strongly correlated
with patients with the less aggressive Luminal A-type
tumours.
In some previous studies CTC status was found to be
considerably less prognostic than DTC status [10,11], in
contrast to the present results. We cannot exclude the
possibility that differences in the prognostic value of
DTC detection in different studies may be due to the
cytokeratin antibody used [33]. However, the novel CTC
detection platform we have employed does offer high
sensitivity and specificity by incorporating multi-marker
Table 5 Prognostic value of CTC and DTC detection in patients subgrouped by ER, PR, and HER2 status (Bold: P >
0.05)
ER PR HER2
Positive Negative Positive Negative Positive Negative
Metastasis-free survival HR 2.2 2.2 2.6 2.3 1.2 2.9
CTC status 95% CI 1.0 to 4.6 1.2 to 4.3 1.2 to 5.9 1.3 to 4.2 0.5 to 2.9 1.6 to 5.1
P-value 0.037 0.015 0.018 0.006 0.691 < 0.001
HR 2.1 1.1 1.6 1.5 1.2 1.6
DTC status 95% CI 1.2 to 3.9 0.5 to 2.4 0.7 to 3.6 0.8 to 2.9 0.5 to 3.0 0.9 to 2.9
P-value 0.015 0.902 0.243 0.179 0.712 0.103
Breast cancer specific survival HR 1.9 2.4 2.0 2.8 1.4 2.9
CTC status 95% CI 0.7 to 4.8 1.2 to 4.6 0.7 to 5.6 1.5 to 5.2 0.5 to 3.4 1.5 to 5.5
P-value 0.180 0.01 0.200 0.001 0.504 0.001
HR 2.9 1.1 1.4 2.0 1.6 1.7
DTC status 95% CI 1.4 to 5.7 0.5 to 2.5 0.5 to 3.9 1.1 to 3.8 0.7 to 4.0 0.9 to 3.3
P-value 0.003 0.832 0.560 0.025 0.268 0.098
CI, confidence interval; CTC, circulating tumour cell; DTC, disseminated tumour cell; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR,
hazard ratio; PR, progesterone receptor
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cell enrichment [20], resulting in increased prognostic
power. This strategy also presents one limitation, how-
ever; by using anti-EpCAM and anti-ErbB2 Micro Beads
for immunoselection, tumour cells that do not express
or express low levels of EpCam or HER2 may not be
enriched. Indeed, CTCs are known to be biologically
heterogeneous (for review see [34]), and able to undergo
phenotypic changes during migration. For example,
some CTCs may lose EpCam in order to intravasate and
reach circulation during epithelial-to-mesenchymal tran-
sition (EMT) [35]. Also, the use of an antibody directed
against HER2 would favour the selection of HER2 posi-
tive CTCs, which may contribute to the observed signifi-
cant overrepresentation of CTC-positive patients who
have HER2-positive tumours.
Although there are biological explanations for differ-
ences in the clinical impact of CTCs and DTCs, different
methodological principles for the detection of CTCs and
DTCs, including the possibility for different sensitivity,
might also contribute to incongruent results. Therefore,
parallel analysis of CTCs and DTCs with the same meth-
odological principle should be encouraged in future trials.
Our CTC assay was originally developed using fresh
PBMCs, and in our previous study demonstrated more
than twice the CTC positivity rate in early-stage patients
than was observed using the liquid nitrogen-stored
material here [2]. The use of our method on fresh
PBMCs would, therefore, be expected to further increase
the sensitivity and clinical utility of the assay. Future
robust prospective studies are warranted to demonstrate
this.
Conclusions
Our results add further evidence for the potential clinical
value of CTC and DTC detection in risk stratification in
early breast cancer. According to our data, approximately
o n ei nf i v eb r e a s tc a n c e rp a t i e n t sa r el i k e l yt ob eC T C
and/or DTC positive at the time of diagnosis and, signifi-
cantly, a proportion of these will be classed as ‘low-risk’
by traditional prognostic measures and may not receive
any form of systemic treatment, yet would probably
derive considerable benefit from it. Our results also sug-
gest that while CTC status may be easier to determine
and monitor than DTC status due to the accessibility of
the sampling material, both CTC and DTC status provide
valuable clinical data that may be indicative of different
disease aspects. Together, these results provide evidence
that CTC and DTC detection generate prognostic infor-
mation that would be useful in a clinical setting.
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